Gerresheimer's SDAX Exit Caps a Year of Unraveling

Gerresheimer fights for survival after accounting scandal leads to technical loan default, asset sales, and a widened BaFin probe, causing a 68% stock plunge.

The formal removal of Gerresheimer from Germany's SDAX index on Friday was a procedural footnote to a far graver reality. The pharmaceutical packaging supplier is fighting for its immediate survival, mired in a technical loan default and scrambling to sell assets as its accounting scandal widens. The company's failure to produce audited financial statements has triggered a chain reaction, leaving its future dependent on the forbearance of its creditors.

At the heart of the crisis are systematic breaches of accounting standards. The company admitted late last year that employees had improperly booked revenue through so-called "bill-and-hold" agreements, recognizing sales before goods were even shipped to customers. This practice has forced corrections of €35 million in revenue and is expected to lead to planned writedowns of up to €240 million. Germany's financial regulator, BaFin, has significantly expanded its probe beyond the 2023/24 financial report to include the period up to May 2025.

The regulatory scrutiny now focuses on several specific discrepancies. Investigators are examining incorrectly reported lease liabilities worth €65.5 million, erroneously stated useful lives for capitalized development costs totaling €29.4 million, and previously unrecognized impairments in the Advanced Technologies segment amounting to €196.5 million. The fallout is spreading to the auditing profession, with the audit oversight body APAS now investigating KPMG, which issued an unqualified audit opinion on the flawed 2024 accounts.

This complete breakdown in financial reporting has paralyzed the company's operations. The release of first-quarter figures and the annual general meeting, originally scheduled for early June, have been indefinitely postponed. The violation of contractual reporting covenants has pushed Gerresheimer into technical default, forcing management into intense negotiations with banks to secure extensions and prevent the cancellation of vital credit lines.

To generate urgent liquidity, the board is pulling the emergency brake. The U.S. drug packaging subsidiary Centor, which was last valued on the books at €292 million, is now on the block. Concurrently, the company will shutter its plant in Chicago Heights by the end of 2026. These drastic measures follow a catastrophic loss of investor confidence, reflected in a share price that has collapsed by approximately 68% over the past twelve months to €17.17.

The SDAX exclusion itself was a foregone conclusion, as index rules require members to publish an audited annual report within four months of their fiscal year-end—a deadline Gerresheimer missed for the year concluded in November 2024. The Bulgarian Shelly Group, a maker of smart controls and sensors, will take its place. While the delisting news prompted only a modest 2.8% drop on the day, the stock had already been decimated in earlier sell-offs. On February 11 alone, the share price plunged roughly 30% as new details of the accounting crisis emerged, with expanded BaFin probes later driving it to its lowest level since 2009.

The index exit creates a fresh technical headwind, as institutional investors whose mandates are tied to index membership face forced selling. Yet some are viewing the extreme weakness as an opportunity. Deka Investment and the CastleKnight Master Fund have recently reported new stake purchases. Market chatter also speculates about a potential takeover by U.S. rival Silgan Holdings, though the absence of reliable financial statements currently blocks any concrete acquisition scenarios.

With the next concrete milestone not expected until June 2026—the postponed deadline for the overdue annual report—the market is left without a reliable basis for valuation. For now, Gerresheimer's short-term fate and its share price trajectory hinge on a single, critical outcome: whether its lenders agree to extend the waivers needed to keep its credit lines intact.